A Study of OTP-01 for Advanced Solid Tumors
This study is testing a new drug called OTP-01 in people with advanced solid tumors. The main goals are to find the best dose of OTP-01, understand its side effects, and see if it can shrink tumors. Researchers will also check how your body processes OTP-01 by taking blood samples. You might be able to join if you are 18 or older and have advanced solid tumors that have progressed after or you couldn't tolerate your most recent treatment. The study aims to enroll about 170 participants. Success would mean finding a safe and effective dose of OTP-01 that can reduce tumor growth.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It aims to enroll 170 participants.
- What's involved
- You will receive OTP-01 through an intravenous (IV) infusion, which will be given no more than once a week. You will also have blood tests to check for safety and drug levels.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety and side effects will be monitored from the start of treatment until up to 36 months after the end of treatment. Tumor progression will also be monitored for up to 36 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors
At a glance
Conditions
NCT07266428
Where you'd take part
This study runs at 14 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Ankara Oncology Training and Research Hospital
Ankara, Turkey (Türkiye)study coordinator listed
Recruiting
Auckland City Hospital
Auckland, New Zealandstudy coordinator listed
Recruiting
Cancer Research SA
Adelaide, Australiastudy coordinator listed
Recruiting
Centro Gaucho Integrado
Porto Alegre, Brazilstudy coordinator listed
Recruiting
Chris O'Brien Lifehouse
Camperdown, Australiastudy coordinator listed
Recruiting
Dana-Farber Cancer Institute
Boston, Massachusettsstudy coordinator listed
Recruiting
Fundación Jiménez Díaz
Madrid, Spainstudy coordinator listed
Recruiting
Hospital de Santa-Maria-Centro Hospitalar Lisboa Norte (CHLN)
Lisbon, Portugalstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Katherine Bell-McGuinn · STUDY_DIRECTOR · Ottimo Pharma Limited
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Phase 1 and Phase 2A: Frequency and Severity of adverse events (AEs) and serious adverse events (SAEs)C1D1 through EoT (up to 36 months)
- Phase 2A - Progression Free Survival (PFS)C1D1 through EoT (up to 36 months)
- Phase 2A - Disease Control Rate (DCR)C1D1 through EoT (up to 36 months)
- Phase 2A - Duration of Response (DOR)C1D1 through EoT (up to 36 months)
- Phase 2A - Objective Response Rate (ORR)C1D1 through EoT (up to 36 months)